ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,567,380 | -42.1% | 483,499 | +3.8% | 0.00% | -100.0% |
| Q2 2023 | $4,437,673 | +4.3% | 465,653 | +20.4% | 0.00% | 0.0% |
| Q1 2023 | $4,255,471 | -25.3% | 386,861 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $5,695,810 | -20.2% | 384,852 | +3.0% | 0.00% | -50.0% |
| Q3 2022 | $7,141,000 | +6.4% | 373,701 | +18.6% | 0.00% | +100.0% |
| Q2 2022 | $6,714,000 | +34.6% | 315,058 | +21.7% | 0.00% | 0.0% |
| Q1 2022 | $4,987,000 | -10.9% | 258,937 | -4.1% | 0.00% | 0.0% |
| Q4 2021 | $5,599,000 | -13.4% | 269,953 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $6,463,000 | -18.4% | 270,519 | -6.8% | 0.00% | 0.0% |
| Q2 2021 | $7,916,000 | +2.6% | 290,103 | +8.7% | 0.00% | 0.0% |
| Q1 2021 | $7,719,000 | +14.2% | 266,818 | +11.1% | 0.00% | 0.0% |
| Q4 2020 | $6,758,000 | +9.7% | 240,255 | +14.3% | 0.00% | 0.0% |
| Q3 2020 | $6,162,000 | +58.8% | 210,268 | +63.8% | 0.00% | 0.0% |
| Q2 2020 | $3,881,000 | +20.1% | 128,330 | +18.3% | 0.00% | 0.0% |
| Q1 2020 | $3,232,000 | – | 108,459 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |